Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
Alcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use...
Two new drug candidates have been developed for the treatment of addiction and depression that have been modelled on the pharmacology of a traditional African psychoactive...
Awakn Life Sciences and the University of Exeter (UoE) are collaborating to put in place a framework for a Phase 3 trial exploring the use of...
Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...
